TAIPEI, June 4, 2024 – REGiMMUNE Limited is pleased to announce that our company has recently been featured in a report by “China Times”. The article highlights our development progress of RGI-2001 and our future IPO plans. We are grateful for the attention and support from “China Times”.
You can read the full article here: 櫃買赴日招商 聚焦生技業
We will continue our commitment to developing RGI-2001 and other innovative drugs in the fields of immunology and oncology.
Ends
About REGiMMUNE Limited
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.
Corporate Contact
Miranda Yu
Investor Relations Manager
REGiMMUNE Corporation Ltd.
+886 2 2555 3377 #511
miranday@regimmune.com
REGiMMUNE瑞格受「中時新聞網」報導
2024年6月4日，台北 – 瑞格國際生技很高興宣布，近日獲得「中時新聞網」的報導，該報導介紹了本公司RGI-2001的開發進度及未來掛牌規劃，感謝「中時新聞網」的關注與支持。
完整報導請見以下連結：櫃買赴日招商 聚焦生技業
我們將致力於推展RGI-2001的研發，並在免疫及癌症領域開發更多創新藥物。
本文結束
關於瑞格國際生技
瑞格係為專注於自體免疫疾病與癌症，運用調控調節性T細胞(Tregs)，開發創新免疫療法之臨床生技公司。瑞格構建之全新候選藥物組合係藉由調控調節性T細胞活性，用於治療免疫疾病及癌症。
媒體聯絡人
余明穎 (Miranda Yu)
投資人關係經理
瑞格國際生技股份有限公司
+886 2 2555 3377 #511
miranday@regimmune.com